Welcome to the Biosimilars Medical Academy, an educational platform designed by medical professionals to provide high quality medical education. The Academy brings you exclusive content in rheumatology, gastroenterology, dermatology and immunology through engaging content.

If you are a Healthcare Professional, please Register with us and receive exclusive updates about our events and new educational resources.

This website is developed and funded by Biogen.

Welcome

Here’s what’s new

Unmet need and limited access

Patient access to biologics is varied and often linked to affordability creating an unmet need.

Immune-mediated infammatory diseases (IMID) are progressive disorders, requiring timely and continuous treatment. Current guidelines often reserve these treatments for patients with more severe disease and/or patients who have failed to respond to multiple other treatments. In some countries, access to biologics may then be further limited by the implementation of national eligibility and reimbursement criteria. This creates an unmet need in many countries worldwide, leaving a gap for biosimilars to fll.

Video resources

Learn through a series of videos of what experts think about some key clinical questions 

11/11/2021 | 12:35

Optimising patient communication Part 1

The crucial role of nurses in optimising patient communication.

11/11/2021 | 12:35

The role of PAGs in switching Part 2

Large-scale advocacy.

Featured publications

Category: Biosimilars Development and evidence Wolff-Holz E, et al.

Evolution of the EU Biosimilar Framework: Past and Future.

The authors of this review focused on the nature and extent of clinical confirmation, in addition to analytical and functional data required by the European Medical Agency (EMA) for the approval of biosimilar products.

Category: Biosimilars Development and evidence European Commission

Biosimilars in the EU: Information Guide for Healthcare Professionals

Since the EU approved the first biosimilar medicine (‘biosimilar’) in 2006, the EU has pioneered the regulation of biosimilars. Over the past 10 years, the EU has approved the highest number of biosimilars worldwide, amassing considerable experience of their use and safety.
This guide has been jointly developed by the EMA and European commission with the objective of providing healthcare professionals with reference information on both the science and regulation underpinning the use of biosimilars.

Category: Biosimilars Development and evidence Kurki P, et al.

Interchangeability of Biosimilars: A European Perspective

The introduction of biosimilars has shown that even complex proteins used for chronic disease treatment can be successfully copied. This in turn triggered discussions on aspects such as interchangeability between biosimilars and their reference products as well as immunogenicity profile of biosimilars.

Featured publications

Category: Biosimilars Development and evidence European Commission

Biosimilars in the EU: Information Guide for Healthcare Professionals

The European Commission has prepared this paper in order to provide payers, physicians and patients with adequate information on biosimilars. It gives a detailed overview of biologics and biosimilars, regulation and development of biosimilars, potential economic consequences of using biosimilars as well as Q&A sections for each of the key stakeholders.

Category: Biosimilars Development and evidence Kurki P, et al.

Interchangeability of Biosimilars: A European Perspective

The introduction of biosimilars has shown that even complex proteins used for chronic disease treatment can be successfully copied. This in turn triggered discussions on aspects such as interchangeability between biosimilars and their reference products as well as immunogenicity profile of biosimilars.

Category: Biosimilars Development and evidence>Wolff-Holz E, et al.

Evolution of the EU Biosimilar Framework: Past and Future.

Lorem, ipsum dolor sit amet consectetur adipisicing elit. Ab placeat eveniet aspernatur repudiandae mollitia temporibus doloremque accusantium iusto laudantium earum quia dignissimos distinctio deleniti facilis ullam consequatur, voluptate veritatis perferendis. Aliquid, vel tenetur expedita ullam, inventore odit, magni reprehenderit aperiam reiciendis aspernatur modi perspiciatis eum in animi eaque commodi? Harum, quisquam et. Quod soluta fugit repellendus cum, provident ratione nobis!

Steering committee

Get introduced to our esteemed faculty members.

Prof. Hubertus H. Nietsch

Prof. Hubertus H. Nietsch

Martin-Luther University of Halle-Wittenberg, Halle (Saale), Germany

Prof. Luis Puig

Prof. Luis Puig

Director of the Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Prof. Hendrik Schulze-Koops

Prof. Hendrik Schulze-Koops

Head of the Department of Rheumatology, Munich University Hospital, Munich, Germany